Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
November 08 2023 - 3:05PM
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today
announced that David-Alexandre C. Gros, M.D., Chief Executive
Officer, will present a company overview at the upcoming Jefferies
London Healthcare Conference on Thursday, November 16, 2023, at
8:00 a.m. GMT (3:00 a.m. EST).
To register in advance for the presentation webcast, sign up
here.
A webcast replay will be accessible following the live session
on the Events page of the Investors section on the Company’s
website at https://ir.eledon.com/news-and-events/events.
About Eledon Pharmaceuticals and
tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology
company that is developing immune-modulating therapies for the
management and treatment of life-threatening conditions. The
Company’s lead investigational product is tegoprubart, an
anti-CD40L antibody with high affinity for CD40 Ligand, a
well-validated biological target within the costimulatory
CD40/CD40L cellular pathway. The central role of CD40L
signaling in both adaptive and innate immune cell activation
and function positions it as an attractive target for
non-lymphocyte depleting, immunomodulatory therapeutic
intervention. The Company is building upon a deep historical
knowledge of anti-CD40 Ligand biology, to conduct preclinical and
clinical studies in kidney allograft transplantation,
xenotransplantation, and amyotrophic lateral sclerosis (ALS).
Eledon is headquartered in Irvine, California. For more
information, please visit the company’s website
at www.eledon.com.
Follow Eledon Pharmaceuticals on social
media: LinkedIn; Twitter
Investor Contact:
Stephen JasperGilmartin Group(858) 525
2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public Relations(212) 253
8881jurban@berrypr.com
Source: Eledon Pharmaceuticals
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From Sep 2023 to Sep 2024